Elazığ Mental Health and Diseases Hospital Psychiatry Clinic
Elâzığ, 23200, Turkey (Türkiye)
Location status: Recruiting
NCT Number: NCT07444879
Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33/sST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.
Interested in participating?
Request Info18 year–65 year
All sexes
Observational
Elâzığ, 23200, Turkey (Türkiye)
Location status: Recruiting
This is an observational, cross-sectional, case-control study conducted at the psychiatry outpatient clinic of Elazığ Mental Health and Diseases Hospital. It was planned to include 40 participants in the panic disorder (PD) and healthy controls (HCs) groups. All participants will complete a sociodemographic data form and the DSM-5 Panic Disorder Severity Scale (Adult Form). Venous blood samples (5 mL) will be collected between 08:30-10:00 a.m. after 12-hour fasting. Serum interleukin-33 (IL-33), soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP) levels will be measured using commercially available ELISA kits. Statistical analyses will include independent samples t-test or Mann-Whitney U test, chi-square test, correlation, regression, and ROC analysis. A p value < 0.05 will be considered statistically significant.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
*Inclusion Criteria:
For PD Group:
*Exclusion Criteria:
For Healthy Control Group:
*Exclusion Criteria:
Time frame: At hospital admission (baseline)
Interleukin-33 (IL-33) levels measured by ELISA (pg/ml).
Time frame: At hospital admission (baseline)
Soluble Suppressor Tumorogenicity-2 (sST2) levels measured by ELISA (pg/ml)
Time frame: At hospital admission (baseline)
C-Reactive Protein (CRP) levels measured by ELISA (mg/dL)
Time frame: At hospital admission (baseline)
Aggregate Index of Systemic Inflammation (AISI) is calculated using the following formula: (neutrophils × monocytes × platelets) / (lymphocytes). All the parameters mentioned here are complete blood count parameters.
Time frame: At hospital admission (baseline)
The DSM-5 Panic Disorder Severity Scale-Adult Form (PDS) is a 10-item self-assessment scale developed by the American Psychiatric Association (APA) that uses a five-point Likert scale (0=Never; 1=Sometimes; 2=Halfway through; 3=Most of the time; 4=Always). Participants consider how much their panic disorder has affected their personal lives in the past seven days when completing the scale. Scores obtained from the scale items indicate the severity of the panic disorder. The scale can be scored between 0 and 40, with higher scores indicating a more severe panic disorder. The mean total score is calculated by dividing the total raw score by the number of items on the scale.
Contact information is provided by the study sponsor or research team.
Elazığ Mental Health and Diseases Hospital
Other Gov
Investigation of IL-33, sST2, and C-Reactive Protein in Panic Disorder: A Cross-Sectional Case-Control Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05868135
Anxiety Disorders, Anxiety, Social
Bergen, Norway
View Trial DetailsNCT05467683
Anxiety Disorders, Generalized Anxiety Disorder
Boston, Massachusetts, United States
View Trial DetailsNCT06563310
Anxiety, Anxiety Disorders
Ann Arbor, Michigan, United States
View Trial DetailsNCT06934525
Agoraphobia, Anxiety
East Providence, Rhode Island, United States
View Trial Details